Common and uncommon egfr mutations analysis in cytology and plasma samples of treatment ‐naive lung cancer patients
Abstract Two novel electrochemiluminescence (ECL) deoxyribosensors are designed for assay of early lung cancer biomarker (NAP2) using the DNA three-way junction (DNA-TWJ) inserted NAP2 binding aptamer between two double-helical stems and labeled with ruthenium (II) complex (Ru) (NBAT-Ru) taken as molecular recognition element. The signal-off ECL deoxyribosensor was fabricated by covalently coupling the 5'-NH2-(CH2)6-NBAT-Ru to glassy carbon electrode surface modified with 4-aminobenzoic acid (4-ABA). After combining NAP2 and NBAT-Ru, the changed conformation of NBAT-Ru altered the distance between Ru complex and e...
[Zimbabwe Standard] Last week the nation woke up to the melancholic news that one of the fast-rising Afro-jazz stars, Prince Kudakwashe Musarurwa, had succumbed to cancer of the lung. It was indeed disconsolate news considering the age of the crooner. He was a strong man who fought for his life till the end. I had the opportunity to attend to him at one of my clinics in Harare. Unfortunately, the disease was already at an advanced stage. May he rest in eternal peace! May my sister Sarah Musarurwa and the entire family find co
CONCLUSIONS: For peripheral lung cancer, the measurement on CT and routine MRI sequences can potentially replace each other after comprehensive consideration of examination purposes, but for central lung cancer, alternative use of CT and MRI in evaluating treatment responses for lung cancer should needs extra attention. The diameter measurement of lung cancer on DWI is consistent with that on T1WI and T2WI, suggesting that DWI can provide functional and morphological information. PMID: 32083610 [PubMed - as supplied by publisher]
Conclusions: Niche mutations exhibited an increased risk of death when compared with EGFR mutations and a similar risk of death when compared with KRAS mutations. PMID: 32082488 [PubMed]
ConclusionNivolumab appeared to be safe and effective in Taiwanese patients. These interim results suggest that nivolumab is a suitable treatment option for this population.Clinical trial registrationNCT02582125.
CONCLUSIONS: We strictly determined prognostic genes of NSCLC, which would contribute to its carcinogenesis investigation and therapeutic methods improvement. PMID: 32083573 [PubMed - as supplied by publisher]
CONCLUSIONS: These results indicated that OCEL1 protein may serve as a novel prognostic biomarker in NSCLC. PMID: 32083572 [PubMed - as supplied by publisher]
CONCLUSIONS: We established a prognostic model for lung adenocarcinoma, and further concluded that SMARCA4, GNAS and TSC2 were a gene signature which plays a prognostic role. PMID: 32083571 [PubMed - as supplied by publisher]
Conclusion: Frozen lung cancer plasma samples stored in the biobank for 1-6 years at -80°C under certain conditions still retain a high level of cfDNA, which is suitable for NGS detection. PMID: 32083487 [PubMed - as supplied by publisher]
ConclusionsThe population PK of PF-06439535 and bevacizumab-EU were well characterized by a two-compartment model. Covariate analysis did not reveal any appreciable differences between PK parameters for PF-06439535 and bevacizumab-EU in patients with NSCLC.Clinical trial registrationClinicalTrials.gov, NCT02364999.